The use of opioid analgesia in end-stage renal disease patients managed without dialysis: Recommendations for practice

Journal of Pain and Palliative Care Pharmacotherapy

Volumn 21, Issue 2, 2007, Pages 5-16

  Murtagh, Fliss E M ^a   Chai, Mee Onn ^b   Donohoe, Paul ^b   Edmonds, Polly M ^b   Higginson, Irene J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Kidney failure; Opioid analgesics; Pain; Pharmacology; Practice guidelines

Indexed keywords

ALFENTANIL; BUPRENORPHINE; CODEINE; DEXTROPROPOXYPHENE; DIAMORPHINE; DIHYDROCODEINE; FENTANYL; HYDROCODONE; HYDROMORPHONE; METHADONE; MORPHINE; MORPHINE DERIVATIVE; NARCOTIC ANALGESIC AGENT; NORBUPRENORHINE; OXYCODONE; PARACETAMOL; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; UNCLASSIFIED DRUG;

ANALGESIA; CHRONIC PAIN; CONSERVATIVE TREATMENT; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EXCRETION; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; KIDNEY CLEARANCE; KIDNEY FAILURE; LOW DRUG DOSE; NONHUMAN; PAIN; PRACTICE GUIDELINE; RECOMMENDED DRUG DOSE; REVIEW; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

ANALGESICS, OPIOID; HUMANS; KIDNEY FAILURE, CHRONIC; PAIN; PALLIATIVE CARE; PRACTICE GUIDELINES;

EID: 34548443321     PISSN: 15360288     EISSN: 15360539     Source Type: Journal    
DOI: 10.1300/J354v21n02_03     Document Type: Review

References (89)

1. National Council for Hospices and Specialist Palliative Care. Briefing-August 2004. Minimum Data Sets Project. 2004. National Council for Hospices and Specialist Palliative Care.
2. Edmonds P. King's College Hospital Palliative Care Team Annual Report 2003-4. 2004. London, King's College Hospital.
3. Standing Medical Advisory Committee and Standing Nursing and Midwifery Advisory Committee. The Principles and Practice of Palliative Care. 1992. London, Standing Medical Advisory Committee and Standing Nursing and Midwifery Advisory Committee.
4. NHS Executive. EL(96)85. A Policy Framework for Commissioning Cancer Services: Palliative Care Services. 1996. London, NHS Executive.
5. Field D, Addington-Hall J. Extending specialist palliative care to all? Soc Sci Med 1999; 48(9):1271-80.
6. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Amer J of Kidney Dis 2002; 39(2 (Suppl 1)):S1-S266.
7. Ansell D, Feest T, editors. UK Renal Registry Report 2003. Renal Registry, Bristol, UK. 2004.
8. United States Renal Data System 2001 Annual Data Report. 2001. Bethesda, MD, USA.
9. Roderick PJ, Ferris G, Feest TG. The provision of renal replacement therapy for adults in England and Wales: recent trends and future directions. QJM 1998; 91(8):581-7.
10. Seale C. Changing patterns of death and dying. Soc Sci Med 2000; 51(6):917-30.
11. Feest TG, Mistry CD, Grimes DS, Mallick NP. Incidence of advanced chronic renal failure and the need for end stage renal replacement treatment. BMJ 1990; 301(6757):897-900.
12. Smith C, Silva-Gane M, Chandna S, Warwicker P, Greenwood R, Farrington K. Choosing not to dialyse: evaluation of planned non-dialytic management in a cohort of patients with end-stage renal failure. Nephron Clinical Practice 2003; 95(2):c40-6.
13. Munshi SK, Vijayakumar N, Taub NA, Bhullar H, Lo TC, Warwick G. Outcome of renal replacement therapy in the very elderly. Nephrol Dial Transplant 2001; 16(1):128-33.
14. Chambers EJ, Germain M, Brown E. Supportive Care for the Renal Patient. 1st ed. Oxford University Press, 2004.
15. Levy JB, Chambers EJ, Brown EA. Supportive care for the renal patient. Nephrol Dial Transplant 2004; 19(6):1357-60.
16. Cohen LM, Reiter GS, Poppel DM, Germain MJ. Renal palliative care. In: Addington-Hall J, Higginson I, editors. Palliative Care for Non-Cancer Patients. Oxford: Oxford University Press, 2001:103-23.
17. Holley JL, Carmody SS, Moss AH, Sullivan AM, Cohen LM, Block SD et al. The need for end-of-life care training in nephrology: national survey results of nephrology fellows. Am J Kidney Dis 2003; 42(4):813-20.
18. Department of Health. National Service Framework for Renal Services-Part 2. 2005. Department of Health, London.
19. Catalano C, Goodship THJ, Graham KA, Marino C, Brown AL, Tapson JS et al. Withdrawal of renal replacement therapy in Newcastle upon Tyne: 1964-1993. Nephrology Dialysis Transplantation 1996; 11(1):133-9.
20. Dean M. Opioids in renal failure and dialysis patients. Journal of Pain & Symptom Management 2004; 28(5):497-504.
21. Davison SN. Pain in hemodialysis patients: prevalence, cause, severity, and management. American Journal of Kidney Diseases 2003; 42(6):1239-47.
22. Angelis M, Wong LL, Myers SA, Wong LM. Calciphylaxis in patients on hemodialysis: a prevalence study. Surgery 1997; 122(6):1083-9.
23. Rich A, Leach A, Ellershaw J. A case of difficult pain in a patient with chronic renal failure and calciphylaxis. Journal of Pain and Symptom Management, 2001; 22: 1; 617-21.
24. World Health Organisation. Cancer pain relief. World Health Organisation, editor. 1986. Geneva, World Health Organisation.
25. http://www.who.int/cancer/palliative/painladder/en/. Internet communication, accessed 22.9.2006
26. Launay-Vacher V, Karie S, Fau JB et al. Treatment of pain in patients with renal insufficiency: the World Health Organization three-step ladder adapted. J of Pain 2005; 6(3):137-48
27. Barakzoy AS, Moss AH. Efficacy of the World Health Organization analgesic ladder to treat pain in end-stage renal disease. JASN Express. Published on September 20, 2006 as doi: 10.1681/ASN.2006050477
28. Broadbent A, Khor K, Heaney A. Palliation and chronic renal failure: opioid and other palliative medications-Dosage guidelines. Progress in Palliative Care, 2003, 11; 4:183-90
29. Vree TB, Verwey-van Wissen CP. Pharmacokinetics and metabolism of codeine in humans. Biopharm Drug Dispos 1992; 13(6):445-60.
30. Guay DR, Awni WM, Findlay JW, Halstenson CE, Abraham PA, Opsahl JA et al. Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease. Clin Pharmacol Ther 1988; 43(1):63-71.
31. Parke TJ, Nandi PR, Bird KJ, Jewkes DA. Profound hypotension following intravenous codeine phosphate. Three case reports and some recommendations. Anaesthesia 1992; 47(10):852-4.
32. Talbott GA, Lynn AM, Levy FH, Zelikovic I. Respiratory arrest precipitated by codeine in a child with chronic renal failure. Clin Pediatr (Phila) 1997; 36(3):171-3.
33. Matzke GR, Chan GL, Abraham PA. Codeine dosage in renal failure. Clin Pharm 1986; 5(1):15-6.
34. Redfern N. Dihydrocodeine overdose treated with naloxone infusion. Br Med J 1983; 287(6394):751-2.
35. Barnes JN, Goodwin FJ. Dihydrocodeine narcosis in renal failure. Br Med J 1983; 286(6363):438-9.
36. Wolen RL, Ziege EA, Gruber CM, Jr. Determination of propoxyphene and norpropoxyphene by chemical ionization mass fragmentography. Clin Pharmacol Ther 1975;17(1):15-20.
37. Gibson TP, Giacomini KM, Briggs WA. Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient. Clin PharmacolTherap 1980, 27; 5: 665-70.
38. Davies G, Kingswood C, Street M. Pharmacokinetics of opioids in renal dysfunction. Clin Pharmacokinet 1996; 31(6):410-22.
39. Nickander R, Smits SE, Steinberg MI. Propoxyphene and norpropoxyphene: pharmacologic and toxic effects in animals. J Pharmacol Exp Ther 1977; 200(1):245- 53.
40. Cone EJ, Darwin WD, Gorodetzky CW, Tan T. Comparative metabolism of hydrocodone in man, rat, guinea pig, rabbit and dog. Drug Metabolism and Disposition 1978;6(4):488-93.
41. Dayer P, Collart L, Desmeules J. The pharmacology of tramadol. Drugs 1994; 47(Suppl 1):3-7.
42. Lee CR, McTavish D, Sorkin EM. Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states. Drugs 1993; 46(2):313-40.
43. Ashley C, Currie A. The Renal Drug Handbook. Second edition ed. Abingdon, UK: Radcliffe Medical Press Ltd, 2004.
44. Gardner JS, Blough D, Drinkard CR, Shatin D, Anderson G, Graham D et al. Tramadol and seizures: a surveillance study in a managed care population. Pharmacother 2000; 20(12):1423-31.
45. Hasselstrom J, Sawe J. Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. Clin Pharmacokinet 1993; 24(4):344-54.
46. Sawe J, Odar-Cederlof I. Kinetics of morphine in patients with renal failure. Eur J Clin Pharmacol 1987; 32(4):377-82.
47. Aitkenhead AR, Vater M, Achola K, Cooper CM, Smith G. Pharmacokinetics of single-dose I.V. morphine in normal volunteers and patients with end-stage renal failure. Br J Anaesth 1984; 56(8):813-9.
48. Wolff J, Bigler D, Christensen CB, Rasmussen SN, Andersen HB, Tonnesen KH. Influence of renal function on the elimination of morphine and morphine glucuronides. Eur J Clin Pharmacol 1988; 34(4):353-7.
49. Bodd E, Jacobsen D, Lund E, Ripel A, Morland J, Wiik-Larsen E. Morphine-6-glucuronide might mediate the prolonged opioid effect of morphine in acute renal failure. Hum Exp Toxicol 1990; 9(5):317-21.
50. Hanna MH, D'Costa F, Peat SJ, Fung C, Venkat N, Zilkha TR et al. Morphine-6-glucuronide disposition in renal impairment. Br J Anaesth 1993; 70(5):511-4.
51. Osborne R, Joel S, Slevin M. Morphine intoxication in renal failure; the role of morphine-6-glucuronide. Br Med J (Clin Res Ed) 1986; 293(6554):1101.
52. Andersen G, Christrup L, Sjogren P. Relationships among morphine metabolism, pain and side effects during long-term treatment: an update. J Pain Symptom Manage 2003; 25(1):74-91.
53. Angst MS, Buhrer M, Lotsch J. Insidious intoxication after morphine treatment in renal failure: delayed onset of morphine-6-glucuronide action. Anesthesiology 2000; 92(5):1473-6.
54. Mercadante S. The role of morphine glucuronides in cancer pain. Palliat Med 1999; 13(2):95-104.
55. Shohami E, Evron S, Weinstock M, Soffer D, Carmon A. A new animal model for action myoclonus. Adv Neurol 1986; 43:545-52.
56. Smith MT, Watt JA, Cramond T. Morphine-3-glucuronide-a potent antagonist of morphine analgesia. Life Sci 1990; 47(6):579-85.
57. Hewett K, Dickenson AH, McQuay HJ. Lack of effect of morphine-3- glucuronide on the spinal antinociceptive actions of morphine in the rat: an electrophysiological study. Pain 1993; 53(1):59-63.
58. Gong QL, Hedner J, Bjorkman R, Hedner T. Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat. Pain 1992; 48(2):249-55.
59. Suzuki N, Kalso E, Rosenberg PH. Intrathecal morphine-3-glucuronide does not antagonize spinal antinociception by morphine or morphine-6-glucuronide in rats. Eur J Pharmacol 1993; 249(2):247-50.
60. Kirkham SR, Pugh R. Opioid analgesia in uraemic patients. Lancet 1995; 345(8958):1185.
61. Hand CW, Sear JW, Uppington J, Ball MJ, McQuay HJ, Moore RA. Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. Br J Anaesth 1990; 64(3):276-82.
62. Mercadante S, Arcuri E. Opioids and renal function. J Pain 2004; 5(1):2-19.
63. Summerfield RJ, Allen MC, Moore RA, Sear JW, McQuay HJ. Buprenorphine in end stage renal failure. Anaesthesia 1985; 40(9):914.
64. Ohtani M, Kotaki H, Nishitateno K, Sawada Y, Iga T. Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine. J Pharmacol Exp Ther 1997; 281(1):428-33.
65. Gueye PN, Borron SW, Risede P, Monier C, Buneaux F, Debray M et al. Buprenorphine and midazolam act in combination to depress respiration in rats. Toxicol Sci 2002; 65(1):107-14.
66. Robson P. The use of opioids in palliative care patients with renal failure. CME Cancer Medicine 2004, 2; 2: 40-8
67. Labroo RB, Paine MF, Thummel KE, Kharasch ED. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab Dispos 1997; 25(9):1072-80.
68. Coral IM, Moore AR, Strunin L. Plasma concentrations of fentanyl in normal surgical patients with severe renal failure. Br J Anaesth 1980; 52:101.
69. Koehntop DE, Rodman JH. Fentanyl pharmacokinetics in patients undergoing renal transplantation. Pharmacotherapy 1997; 17(4):746-52.
70. Bentley JB, Borel JD, Nenad RE, Jr., Gillespie TJ. Age and fentanyl pharmacokinetics. Anesth Analg 1982; 61(12):968-71.
71. palliativedrugs.com 2003. Internet communication, accessed 12.5.2005
72. Meuldermans W, Van Peer A, Hendrickx J, Woestenborghs R, Lauwers W, Heykants J et al. Alfentanil pharmacokinetics and metabolism in humans. Anesthesiology 1988; 69(4):527-34.
73. Scholz J, Steinfath M, Schulz M. Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update. Clin Pharmacokinet 1996; 31(4):275-92.
74. Durnin C, Hind ID, Wickens MM, Yates DB, Molz KH. Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in subjects with renal impairment. Proc West Pharmacol Soc 2001; 44:81-2.
75. Babul N, Darke AC, Hagen N. Hydromorphone metabolite accumulation in renal failure. J Pain Symptom Manage 1995; 10(3):184-6.
76. Wright AW, Mather LE, Smith MT. Hydromorphone-3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide. Life Sci 2001; 69(4):409-20.
77. Fainsinger R, Schoeller T, Boiskin M, Bruera E. Palliative care round: cognitive failure and coma after renal failure in a patient receiving captopril and hydromorphone. J Palliat Care 1993; 9(1):53-5.
78. Kurella M, Bennett WM, Chertow GM. Analgesia in patients with ESRD: A review of available evidence. Amer J Kidney Dis 2003, 42; (2): 217-28.
79. Lee MA, Leng ME, Tiernan EJ. Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine. Palliat Med 2001; 15(1):26-34.
80. Farrell A, Rich A. Analgesic use in patients with renal failure. European Journal of Palliative Care 2000; 7(6):201-5.
81. Kreek MJ, Schecter AJ, Gutjahr CL, Hecht M. Methadone use in patients with chronic renal disease. Drug Alcohol Depend 1980; 5(3):197-205.
82. Morley JS, Makin MK. The use of methadone in cancer pain poorly responsive to other opioids. Pain Reviews 1998; 5:51-8.
83. Blackburn D, Somerville E, Squire J. Methadone: an alternative conversion regime. Europ J Palliat Care 2002; 9(3):93-6.
84. Kirvela M, Lindgren L, Seppala T, Olkkola KT. The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. J Clin Anesth 1996; 8(1):13-8.
85. Kaiko RF, Benziger DP, Fitzmartin RD, Burke BE, Reder RF, Goldenheim PD. Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone. Clin Pharmacol Ther 1996; 59(1):52-61.
86. Poyhia R, Vainio A, Kalso E. A review of oxycodone's clinical pharmacokinetics and pharmacodynamics. J Pain Symptom Manage 1993; 8(2):63-7.
87. Heiskanen T, Olkkola KT, Kalso E. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 1998; 64(6):603-11.
88. Kalso E, Vainio A, Mattila MJ, Rosenberg PH, Seppala T. Morphine and oxycodone in the management of cancer pain: plasma levels determined by chemical and radioreceptor assays. Pharmacol Toxicol 1990; 67(4):322-8.
89. Fitzgerald J. Narcotic analgesics in renal failure. Conn Med 1991; 55(12):701-4.